{"source_content":"http://research.stocke.com.cn1/5请务必阅读正文之后的免责条款部分[Table_main]公司研究类模板点评报告爱美客(300896)报告日期：2020年10月27日嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发──爱美客跟踪点评[table_zw]公司研究类模板公司研究｜医美及化妆品｜：分析师：马莉执业证书编号：S1230520070002：联系人：陈腾曦、林骥川、詹陆雨：mali@stocke.com.cn报告导读嗨体等明星产品带动Q3收入/归母净利同增43%/56%，展现超预期增长。投资要点❑事件：公司公布三季报，Q1-Q3收入同比增长17.4%至4.64亿元，归母净利同比增长31.8%至2.90亿元，高于此前招股说明书中前三季度归母净利同增18%-27%至2.6-2.8亿元的预期；单季度来看，Q3公司营收同比增长43%至2.23亿元,归母净利同比增长56%至1.43亿元，扣非归母净利增长56%至1.39亿元，展现超预期增长。❑超预期增长来自以嗨体为代表的明星产品销售蓬勃以及规模效应下的盈利能力提升。公司2020Q1/Q2/Q3单季度收入同比-21%/+16%/43%至0.79/1.63/2.23亿元，疫情后逐季加速趋势非常明显，主要来自明星产品嗨体的带动，嗨体作为NMPA唯一认证颈纹改善III类医疗器械在Q1/Q2收入增速高达28%/76%，强增长延续至Q3，叠加疫情后随下游客户逐渐恢复营业，爱芙莱、宝尼达等其他产品销售也实现有效恢复，带来三季度收入高增。收入高增同时，公司上半年受疫情影响毛利率略有1.9pp下滑至90.2%，但Q3单季度已经基本恢复去年同期毛利率水准，达到93.0%，由此前三季度毛利率降幅缩窄至1.1pp，毛利率达到91.5%；毛利率维持高位同时，公司前三季度销售费用同比下降412万元，销售费用率同比下降2.7pp，主要得益于嗨体为代表的经销渠道业务在本年度的积极发展，同时前三季度管理费用同比下降903万元，管理费用率同比降3.3pp至9.0%，体现疫情下进一步控费提效，与此同时研发费用持续上行，前三季度达到3306万，持续研发投入为未来产品矩阵进一步丰富打下基础，但受益收入高增带来的费用率摊薄，研发费用率降0.7pp至7.1%。由此，收入高增+毛利率维持高位+规模效应下费用率显著下行，带来公司前三季度/单三季度归母净利同增32%/56%至2.9/1.4亿元，表现超预期。也受益优秀的盈利表现与稳定的营运资本周转，公司前三季度/单三季度经营性现金流同比增长20%/49%至2.6/1.4亿元。❑盈利预测及估值：考虑到Q3盈利超预期，我们上调盈利预测，预计2020/21/22年公司收入同比增长23%/49%/45%至6.8/10.2/14.8亿元，归母净利同比增长34%/47%/46%至4.1/6.0/8.8亿元，对应当前市值PE为143/98/67X，公司在注射医美领域领先优势明显、产品及产能储备充足，增长潜力突出，值得长期重点关注，考虑估值及成长性，维持“增持”评级。❑风险提示：新产品开发和注册风险，下游客户风险[table_invest]评级增持上次评级增持当前价格￥490.08单季度业绩元/股3Q/20201.56[table_stktrend]公司简介专注生物医用软组织修复材料领域，旗下拥有6款国家药监局获批III类医疗器械产品，包括嗨体、爱芙莱、宝尼达、逸美等5款透明质酸钠系列产品及1款面部埋植线产品，国内医美用透明质酸领域市场份额2019年达到14%，列本土企业之首相关报告1、《爱美客：注射医美领域先驱，丰富产品矩阵尽享行业红利》2020-10-08覆盖研究员消费分析师：马莉执业证书编号：S1230520070002mali@stocke.com.cn消费分析师：詹陆雨执业证书编号：S1230520070005zhanluyu@stocke.com.cn中小盘分析师：余剑秋执业证书编号：S1230520080007yujianqiu@stocke.com.cn中小盘研究助理：汤秀洁tangxiujie@stocke.com.cn报告撰写人：马莉、余剑秋联系人：詹陆雨、汤秀洁证券研究报告[table_page]爱美客(300896)深度报告http://research.stocke.com.cn2/5请务必阅读正文之后的免责条款部分财务摘要[table_predict]（百万元）20192020E2021E2022E主营收入557.7683.21019.91479.8(+/-)73.7%22.5%49.3%45.1%净利润305.5409.9602.8879.9(+/-)148.7%34.2%47.1%46.0%每股收益（元）3.393.415.027.32P/E192.8143.797.766.9表：爱美客财务三表摘要（单位：百万元）2017201820192019H12020H12019Q1-Q32020Q1-Q32019Q32020Q3利润表摘要营业收入222.49321.01557.72240.17241.90395.59464.44155.42222.54YOY44.3%73.7%0.7%17.4%43.2%毛利润191.67286.79516.62221.21218.25366.19425.14144.98206.89YOY49.6%80.1%-1.3%16.1%42.7%毛利率86.1%89.3%92.6%92.1%90.2%92.6%91.5%93.3%93.0%期间费用95.40138.81172.1172.9058.73111.75100.4838.8541.74YOY45.5%24.0%-19.4%-10.1%7.4%期间费用率42.9%43.2%30.9%30.4%24.3%28.2%21.6%25.0%18.8%销售费用41.9162.4177.1729.6223.5946.1442.0216.5218.42销售费用率18.8%19.4%13.8%12.3%9.8%11.7%9.0%10.6%8.3%管理费用25.7044.4448.0923.6415.2035.6726.6412.0311.44管理费用率11.6%13.8%8.6%9.8%6.3%9.0%5.7%7.7%5.1%研发费用28.4933.6848.5620.4220.8130.9033.0610.4812.25研发费用率12.8%10.5%8.7%8.5%8.6%7.8%7.1%6.7%5.5%财务费用(0.70)(1.72)(1.71)(0.78)(0.87)(0.96)(1.24)(0.18)(0.37)财务费用率-0.3%-0.5%-0.3%-0.3%-0.4%-0.2%-0.3%-0.1%-0.2%加：其他收益0.631.772.810.570.710.831.250.260.54投资净收益2.780.756.972.166.274.598.492.432.22营业利润93.70143.27350.21148.83165.10256.66333.61107.83168.51YOY52.9%144.4%10.9%30.0%56.3%营业利润率42.1%44.6%62.8%62.0%68.3%64.9%71.8%69.4%75.7%利润总额93.70143.19350.79148.77165.10256.58333.61107.81168.51YOY52.8%145.0%11.0%30.0%56.3%所得税率18.1%18.9%15.1%16.0%12.9%16.4%14.4%17.0%15.8%净利润76.73116.13297.97124.91143.86214.41285.6989.49141.83YOY51.3%156.6%15.2%33.2%58.5%净利率34.5%36.2%53.4%52.0%59.5%54.2%61.5%57.6%63.7%减：少数股东损益(5.46)(6.73)(7.55)(3.63)(3.44)(5.91)(4.75)(2.28)(1.31)归母净利82.19122.85305.52128.54147.29220.32290.4391.77143.14YOY49.5%148.7%14.6%31.8%56.0%资产负债表摘要货币资金214.35265.55505.61172.36316.42未披露3543.33未披露3543.33交易性金融资产280.40672.17672.17应收账款4.409.1214.7412.3320.6428.8128.81YOY107.3%61.6%67.4%存货17.5312.9723.2919.3821.8927.7227.72YOY-26.0%79.6%13.0%固定资产100.97138.35150.64140.14146.26144.47144.47资产总计396.41463.61743.65547.25869.204502.404502.40负债合计68.0958.8780.9562.5162.64118.87118.87所有者权益合计328.31404.74662.70484.74806.564383.524383.52[table_page]爱美客(300896)深度报告http://research.stocke.com.cn3/5请务必阅读正文之后的免责条款部分现金流量表摘要经营现金流量净额84.16135.50309.72118.52115.28215.12258.7596.60143.46YOY61.0%128.6%-2.7%20.3%48.5%/净利润110%117%104%95%80%100%91%108%101%投资现金流量净额(11.10)(38.41)(25.62)(163.68)(303.89)(294.55)(694.34)(130.87)(390.46)筹资现金流量净额(12.40)(45.89)(44.03)(48.03)(0.59)(48.43)3473.32(0.40)3473.90现金及等价物净增60.6651.20240.06(93.19)(189.19)(127.86)3037.72(34.67)3226.91数据来源：Wind，浙商证券研究所[table_page]爱美客(300896)深度报告http://research.stocke.com.cn4/5请务必阅读正文之后的免责条款部分表附录：三大报表预测值[table_money]资产负债表利润表单位：百万元20192020E2021E2022E单位：百万元20192020E2021E2022E流动资产5654,2494,6005,134营业收入5586831,0201,480现金5064,1684,4974,987营业成本415583123交易性金融资产0000营业税金及附加4469应收账项15173038营业费用7779117170其它应收款2569管理费用48445667预付账款571014研发费用495582111存货23323765财务费用-2-12-22-24其他14202020资产减值损失000-1非流动资产179348494681公允价值变动损益0000金额资产类0000投资净收益7101010长期投资0141414其他经营收益3333固定资产151246339522营业利润3504707091,035无形资产11151821营业外收支1111在建工程050100100利润总额3514717101,036其他18222324所得税5371107156资产总计7444,5975,0955,816净利润298400603880流动负债6779108139少数股东损益-8-10-15-15短期借款0000归属母公司净利润306410603880应付款项7151931EBITDA3674767031,037预收账款10101320EPS（最新摊薄）3.393.415.027.32其他50557689主要财务比率非流动负债1420243020192020E2021E2022E长期借款0000成长能力其他14202430营业收入73.7%22.5%49.3%45.1%负债合计8199132169营业利润144.4%34.1%50.9%46.0%少数股东权益4-6-21-36归属母公司净利润148.7%34.2%47.1%46.0%归属母公司股东权6594,5044,9845,683获利能力负债和股东权益7444,5975,0955,816毛利率92.6%91.9%91.8%91.7%净利率53.4%58.5%59.1%59.5%现金流量表ROE57.2%15.9%12.7%16.6%单位：百万元20192020E2021E2022EROIC46.0%8.8%11.7%15.1%经营活动现金流310376583848偿债能力净利润298400603880资产负债率10.9%2.2%2.6%2.9%折旧摊销1061524净负债比率12.2%2.2%2.7%3.0%财务费用0-12-22-24流动比率8.453.642.636.8投资损失-7-10-10-10速动比率8.053.142.236.3营运资金变动7-11-3-24营运能力其它2312总资产周转率0.90.30.20.3投资活动现金流-26-106-132-178应收帐款周转率42.840.040.040.0资本支出33156161211应付帐款周转率2.95.05.05.0长期投资0000每股指标(元)其他-7-51-29-33每股收益3.393.415.027.32筹资活动现金流-443,392-123-181每股经营现金3.443.134.857.06短期借款0000每股净资产7.3237.4741.4647.28长期借款0000估值比率其他-443,392-123-181P/E192.8143.797.766.9现金净增加额2403,663329490P/B89.413.111.810.4EV/EBITDA159.3115.177.452.0资料来源：浙商证券研究所[table_page]爱美客(300896)深度报告http://research.stocke.com.cn5/5请务必阅读正文之后的免责条款部分股票投资评级说明以报告日后的6个月内，证券相对于沪深300指数的涨跌幅为标准，定义如下：1、买入：相对于沪深300指数表现＋20％以上；2、增持：相对于沪深300指数表现＋10％～＋20％；3、中性：相对于沪深300指数表现－10％～＋10％之间波动；4、减持：相对于沪深300指数表现－10％以下。行业的投资评级：以报告日后的6个月内，行业指数相对于沪深300指数的涨跌幅为标准，定义如下：1、看好：行业指数相对于沪深300指数表现＋10%以上；2、中性：行业指数相对于沪深300指数表现－10%～＋10%以上；3、看淡：行业指数相对于沪深300指数表现－10%以下。我们在此提醒您，不同证券研究机构采用不同的评级术语及评级标准。我们采用的是相对评级体系，表示投资的相对比重。建议：投资者买入或者卖出证券的决定取决于个人的实际情况，比如当前的持仓结构以及其他需要考虑的因素。投资者不应仅仅依靠投资评级来推断结论法律声明及风险提示本报告由浙商证券股份有限公司（已具备中国证监会批复的证券投资咨询业务资格，经营许可证编号为：Z39833000）制作。本报告中的信息均来源于我们认为可靠的已公开资料，但浙商证券股份有限公司及其关联机构（以下统称“本公司”）对这些信息的真实性、准确性及完整性不作任何保证，也不保证所包含的信息和建议不发生任何变更。本公司没有将变更的信息和建议向报告所有接收者进行更新的义务。本报告仅供本公司的客户作参考之用。本公司不会因接收人收到本报告而视其为本公司的当然客户。本报告仅反映报告作者的出具日的观点和判断，在任何情况下，本报告中的信息或所表述的意见均不构成对任何人的投资建议，投资者应当对本报告中的信息和意见进行独立评估，并应同时考量各自的投资目的、财务状况和特定需求。对依据或者使用本报告所造成的一切后果，本公司及/或其关联人员均不承担任何法律责任。本公司的交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本报告意见及建议不一致的市场评论和/或交易观点。本公司没有将此意见及建议向报告所有接收者进行更新的义务。本公司的资产管理公司、自营部门以及其他投资业务部门可能独立做出与本报告中的意见或建议不一致的投资决策。本报告版权均归本公司所有，未经本公司事先书面授权，任何机构或个人不得以任何形式复制、发布、传播本报告的全部或部分内容。经授权刊载、转发本报告或者摘要的，应当注明本报告发布人和发布日期，并提示使用本报告的风险。未经授权或未按要求刊载、转发本报告的，应当承担相应的法律责任。本公司将保留向其追究法律责任的权利。浙商证券研究所上海总部地址：杨高南路729号陆家嘴世纪金融广场1号楼29层北京地址：北京市广安门大街1号深圳大厦4楼深圳地址：深圳市福田区深南大道2008号凤凰大厦2栋21E02邮政编码：200127电话：(8621)80108518传真：(8621)80106010浙商证券研究所：http://research.stocke.com.cn","data":[{"id":"1","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"Q1-Q3收入同比增长17.4%至4.64亿元","content_offset":["279","302"],"indicators":[{"indicator_name":"收入同比","indicator_value":["17.4%","290","295"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q1-Q3","279","284"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"Q1-Q3收入同比增长17.4%至4.64亿元","content_offset":["279","302"],"indicators":[{"indicator_name":"收入","indicator_value":["4.64亿元","296","302"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q1-Q3","279","284"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"归母净利同比增长31.8%至2.90亿元","content_offset":["303","323"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["31.8%","311","316"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q1-Q3","279","284"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"归母净利同比增长31.8%至2.90亿元","content_offset":["303","323"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.90亿元","317","323"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q1-Q3","279","284"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"Q3公司营收同比增长43%至2.23亿元","content_offset":["371","391"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["43%","381","384"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q3","371","373"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"Q3公司营收同比增长43%至2.23亿元","content_offset":["371","391"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2.23亿元","385","391"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q3","371","373"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"归母净利同比增长56%至1.43亿元","content_offset":["392","410"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["56%","400","403"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q3","371","373"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"归母净利同比增长56%至1.43亿元","content_offset":["392","410"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["1.43亿元","404","410"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q3","371","373"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"扣非归母净利增长56%至1.39亿元","content_offset":["411","429"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["56%","419","422"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q3","371","373"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"扣非归母净利增长56%至1.39亿元","content_offset":["411","429"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["1.39亿元","423","429"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["Q3","371","373"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"公司2020Q1/Q2/Q3单季度收入同比-21%/+16%/43%至0.79/1.63/2.23亿元","content_offset":["476","527"],"indicators":[{"indicator_name":"收入同比","indicator_value":["-21%","497","501"],"indicator_element":{"时间":["2020Q1","478","484"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入同比","indicator_value":["+16%","502","506"],"indicator_element":{"时间":["Q2","485","487"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入同比","indicator_value":["43","507","509"],"indicator_element":{"时间":["Q3","488","490"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"公司2020Q1/Q2/Q3单季度收入同比-21%/+16%/43%至0.79/1.63/2.23亿元","content_offset":["476","527"],"indicators":[{"indicator_name":"收入","indicator_value":["0.79","511","515"],"indicator_element":{"时间":["2020Q1/Q2/Q3","478","490"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入","indicator_value":["1.63","516","520"],"indicator_element":{"时间":["2020Q1/Q2/Q3","478","490"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入","indicator_value":["2.23亿元","521","527"],"indicator_element":{"时间":["2020Q1/Q2/Q3","478","490"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"嗨体作为NMPA唯一认证颈纹改善III类医疗器械在Q1/Q2收入增速高达28%/76%","content_offset":["556","599"],"indicators":[{"indicator_name":"收入同比","indicator_value":["28%","592","595"],"indicator_element":{"时间":["Q1","581","583"],"产品":["嗨体","556","558"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入同比","indicator_value":["76%","596","599"],"indicator_element":{"时间":["Q2","584","586"],"产品":["嗨体","556","558"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"公司上半年受疫情影响毛利率略有1.9pp下滑至90.2%，但Q3单季度已经基本恢复去年同期毛利率水准，达到93.0%，由此前三季度毛利率降幅缩窄至1.1pp，毛利率达到91.5%","content_offset":["665","754"],"indicators":[{"indicator_name":"毛利率","indicator_value":["90.2%","688","693"],"indicator_element":{"时间":["上半年","667","670"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["93.0%","718","723"],"indicator_element":{"时间":["Q3","695","697"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["91.5%","749","754"],"indicator_element":{"时间":["前三季度","726","730"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"公司前三季度销售费用同比下降412万元","content_offset":["765","784"],"indicators":[{"indicator_name":"销售费同比","indicator_value":["下降412万元","777","784"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","767","771"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"销售费用率同比下降2.7pp","content_offset":["785","799"],"indicators":[{"indicator_name":"销售费用率同比 ","indicator_value":["下降2.7pp","792","799"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","726","730"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"同时前三季度管理费用同比下降903万元","content_offset":["827","846"],"indicators":[{"indicator_name":"管理费同比","indicator_value":["下降903万元","839","846"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","829","833"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"管理费用率同比降3.3pp至9.0%","content_offset":["847","865"],"indicators":[{"indicator_name":"管理费用率同比","indicator_value":["降3.3pp","854","860"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","767","771"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"管理费用率同比降3.3pp至9.0%","content_offset":["847","865"],"indicators":[{"indicator_name":"管理费用率","indicator_value":["9.0%","861","865"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","767","771"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"前三季度达到3306万","content_offset":["892","903"],"indicators":[{"indicator_name":"研发费用","indicator_value":["3306万","898","903"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","892","896"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"研发费用率降0.7pp至7.1%","content_offset":["943","959"],"indicators":[{"indicator_name":"研发费用率同比","indicator_value":["降0.7pp","948","954"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","892","896"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"研发费用率降0.7pp至7.1%","content_offset":["943","959"],"indicators":[{"indicator_name":"研发费用率","indicator_value":["7.1%","955","959"],"indicator_element":{"公司":["爱美客","1499","1502"],"时间":["前三季度","892","896"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"带来公司前三季度/单三季度归母净利同增32%/56%至2.9/1.4亿元","content_offset":["989","1025"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["32%","1008","1011"],"indicator_element":{"时间":["前三季度","993","997"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["56%","1012","1015"],"indicator_element":{"时间":["单三季度","998","1002"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"带来公司前三季度/单三季度归母净利同增32%/56%至2.9/1.4亿元","content_offset":["989","1025"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.9","1016","1019"],"indicator_element":{"时间":["前三季度","993","997"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["1.4亿元","1020","1025"],"indicator_element":{"时间":["单三季度","998","1002"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"公司前三季度/单三季度经营性现金流同比增长20%/49%至2.6/1.4亿元","content_offset":["1053","1091"],"indicators":[{"indicator_name":"经营性现金流同比","indicator_value":["20%","1074","1077"],"indicator_element":{"时间":["前三季度","1055","1059"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"经营性现金流同比","indicator_value":["49%","1078","1081"],"indicator_element":{"时间":["单三季度","1060","1064"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"公司前三季度/单三季度经营性现金流同比增长20%/49%至2.6/1.4亿元","content_offset":["1053","1091"],"indicators":[{"indicator_name":"经营性现金流","indicator_value":["2.6","1082","1085"],"indicator_element":{"时间":["前三季度","1055","1059"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"经营性现金流","indicator_value":["1.4亿元","1086","1091"],"indicator_element":{"时间":["单三季度","1060","1064"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"预计2020/21/22年公司收入同比增长23%/49%/45%至6.8/10.2/14.8亿元","content_offset":["1121","1169"],"indicators":[{"indicator_name":"收入同比","indicator_value":["23%","1142","1145"],"indicator_element":{"时间":["2020","1123","1127"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入同比","indicator_value":["49%","1146","1149"],"indicator_element":{"时间":["21","1128","1130"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入同比","indicator_value":["45%","1150","1153"],"indicator_element":{"时间":["22年","1131","1134"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"预计2020/21/22年公司收入同比增长23%/49%/45%至6.8/10.2/14.8亿元","content_offset":["1121","1169"],"indicators":[{"indicator_name":"收入","indicator_value":["6.8","1154","1157"],"indicator_element":{"时间":["2020","1123","1127"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入","indicator_value":["10.2","1158","1162"],"indicator_element":{"时间":["21","1128","1130"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入","indicator_value":["14.8亿元","1163","1169"],"indicator_element":{"时间":["22年","1131","1134"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"归母净利同比增长34%/47%/46%至4.1/6.0/8.8亿元","content_offset":["1170","1203"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["34%","1178","1181"],"indicator_element":{"时间":["2020","1123","1127"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["47%","1182","1185"],"indicator_element":{"时间":["21","1128","1130"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["46%","1186","1189"],"indicator_element":{"时间":["22年","1131","1134"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"归母净利同比增长34%/47%/46%至4.1/6.0/8.8亿元","content_offset":["1170","1203"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["4.1","1190","1193"],"indicator_element":{"时间":["2020","1123","1127"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["6.0","1194","1197"],"indicator_element":{"时间":["21","1128","1130"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["8.8亿元","1198","1203"],"indicator_element":{"时间":["22年","1131","1134"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"爱美客（300896）跟踪评论：嗨体带动Q3业绩超预期，医美龙头增长潜力持续爆发.pdf","content":"对应当前市值PE为143/98/67X","content_offset":["1204","1223"],"indicators":[{"indicator_name":"估值","indicator_value":["143","1213","1216"],"indicator_element":{"时间":["2020","1123","1127"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"估值","indicator_value":["98","1217","1219"],"indicator_element":{"时间":["21","1128","1130"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}},{"indicator_name":"估值","indicator_value":["67X","1220","1223"],"indicator_element":{"时间":["22年","1131","1134"],"公司":["爱美客","1499","1502"]},"indicator_supplement":{"属性":""}}]}]}